Krsnaa Diagnostics has announced the resignation of its Chief Financial Officer, Mr. Pawan Daga, effective January 19, 2026. The healthcare diagnostics company informed stock exchanges about this key managerial personnel change through a regulatory filing on January 15, 2026.

Resignation Details

The company filed the disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. According to the filing, Daga's last working day will be until the close of business hours on January 19, 2026.

Management's Acknowledgment

The management has placed on record its sincere appreciation for Daga's services during his five-year tenure with Krsnaa Diagnostics. The company specifically acknowledged his contribution to the organization's growth during this period.

In his resignation letter dated January 15, 2026, Daga expressed gratitude for the trust, opportunities, and support extended by the Board and management team. He highlighted his experience working with the finance function and various financial and strategic initiatives aimed at strengthening the company's financial health and governance framework.

Regulatory Compliance

The disclosure was made in compliance with multiple SEBI regulations and circulars, including:

• Regulation 30(6) read with clause 7C of Para A of Part A of schedule III of the SEBI Listing Regulations
• SEBI Circular No SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024
• SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024

The filing was signed by Sujoy Sudipta Bose, Company Secretary and Compliance Officer of Krsnaa Diagnostics Limited. The company has confirmed that there are no other reasons beyond personal and professional priorities for the CFO's resignation.

About the Departure

Daga confirmed in his resignation letter that the decision was made after careful consideration of his personal and professional priorities. He expressed confidence that the finance function is well-positioned for continued success and conveyed his thanks to the Board, senior management team, and colleagues for the enriching experience.

Krsnaa Diagnostics has received board approval for the issuance of Non-Convertible Debentures (NCDs) worth ₹430.00 crores, following its earlier regulatory approval. The board meeting held on December 12, 2025, which commenced at 11:30 AM and concluded at 12:40 PM, formally approved the issuance of unlisted, secured, redeemable and transferable NCDs on a private placement basis.

Board Meeting and Approval Details

The company's board of directors has provided comprehensive approval for the NCD structure and terms. The following table outlines the key decisions made during the board meeting:

NCD Structure and Terms

The approved NCDs will have a structured repayment mechanism with specific tenure and interest payment schedules. The debentures are designed as unlisted, secured instruments with comprehensive terms for investor protection.

Security and Redemption Framework

The NCDs will be secured through charges created over identified assets of the company as per definitive agreements. The redemption structure provides for systematic repayment commencing six months from the allotment date, with both interest and principal payable on a half-yearly basis through thirteen equal instalments.

The debentures will carry all rights and privileges as provided under the Companies Act, 2013, and terms specified in the definitive agreements. This structured approach ensures investor protection while providing the company with medium-term funding solutions.

Strategic Capital Access

This board approval follows the earlier regulatory clearance, enabling Krsnaa Diagnostics to access debt capital markets through the private placement route. The NCD issuance provides the healthcare diagnostics company with an alternative financing mechanism beyond traditional banking channels, supporting its operational requirements and growth initiatives in the competitive healthcare sector.